2021.Mar.17
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
1. Date of occurrence of the event: Mar 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. Reciprocal shareholding ratios: No applicable 5. Cause of occurrence: OBI filed the application to EMA for Phase III human clinical study of the active cancer […]
This article is password protected.
To view the content, please enter your password in the field below